IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent A	application of					
OXFORD et a	al	Atty. Ref.:	620-288			
Serial No.	10/766,030	Group:	1625			
Filed: Ja	nuary 29, 2004	Examiner:	DENTZ, Bernard I.			
For: EP4 F	RECEPTOR ANTAGONISTS					
	* * * * * * *	* * * *				
Commissione P.O. Box 145 Alexandria, V		September	21, 2006			
Sir:	INFORMATION DISCLOSURE	STATEMEN ⁻	<u>[</u>			
<u> </u>	PTO-1449 Pursuant to 37 CFR 1.97(kg) [within 3 months of filing or prior to 1st]	•	on the merits] <i>N/C</i>			
2.(a)	2.(a) Statement Pursuant to 37 CFR 1.97(c) [before Final Office Action or Allowance (requires Rule 97(e) Statement or Rule 17(p) fee)] N/C					
	Fee Payment Pursuant to 37 CFR 1.9 [before Final Office Action or Allowance Statement or Rule 17(p) fee)]		ule 97(e) <i>\$180.00</i>			
3.	Pursuant to 37 CFR 1.97(d) [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment] \$180.00					

The following are submitted in the above-identified application in compliance with 37 C.F.R. §§ 1.97 and 1.98: \bowtie 4. A list of documents on Form PTO-1449 together with copies of each identified document and a translation or a concise explanation of each non-English language document (such as a Search Report) is enclosed herewith. This paper is submitted in accordance with: 5. 37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action] \boxtimes 6. 37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; and a) The required Statement made in item 8 below; or \boxtimes b) The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below. 7. 37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee paymentl; and The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; and П b) The required Statement is stated in item 8 below. 8. Statement under 37 CFR 1.97(e) П a) The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or b) No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

9.	Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.
	Respectfully submitted,
	NIXON & VANDERHYE P.C.

By: /B. J. Sadoff/
B. J. Sadoff
Reg. No. 36,663

901 North Glebe Road, 11th Floor Arlington, VA 22203-1808 Telephone: (703) 816-4000

Facsimile: (703) 816-4100

	ATTY. DOCKET NO.	SERIAL NO.	
	620-888	10/766,030	
INFORMATION DISCLOSURE STATEMENT	APPLICANT		
	Oxford et al		
(Use several sheets if necessary)	FILING DATE	GROUP	
	01/09/2004	1625	

U.S. PATENT DOCUMENTS

			U	S. I ATENT DOCUMENTS			
*Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	1	5,834,468	11/1998	Breault et al			
	2	6,184,245	02/2001	Yugi Sugawara et al			
	4	2003/158240	08/2003	Gordon Baxter et al			
	5	6,610,719	08/2003	Vishwas Paralkar et al			
	6	6,380,218	04/2002	Anthony Moarfat et al			
	7	2005/043386	02/2005	Takahide Nishi et al			
	8	5,602,136	02/1997	Gerd Ruhter et al			
	9	5,686,445	11/1997	Jay Albright et al			
	12	2003/100583	05/2003	Jean-Michel Bernardon			
	13	2003/119817	06/2003	Anita Mehta et al			
	14	2004/0147559	07/2004	Arthur Taveras et al			
	15	2004/0152734	08/2004	Corrina Sundermann et al			
	16	2004/0235888	11/2004	Teruo Yamamori et al			
	17	2005/176987	08/2004	Lukas Goossen et al			
	18	2002/0115671	08/2002	R Goehring et al			
	19	5,607,951	03/1997	John Macor et al			
	20	5,679,692	10/1997	Richard Friary et al			
	21	5,883,106	03/1999	Rodney W Stevens et al			
	22	5,977,170	11/1999	Thomas Commons et al			
	23	6,008,362	12/1999	Thomas Commons et al			
	24	6,121,671	08/2000	Kei-Yu Ko et al			
_	25	6,162,819	12/2000	Ursula Schindler et al			
	26	6,291,677	09/2001	Jayasree Vasudevan et al			
	27	6,849,641	02/2005	Peng Cho Tang et al			

Examiner	Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

U.S. PATENT DOCUMENTS

	28	6,956,057	10/2005	David F Woodward et al		
	31	6,211,197	04/2001	Michel Belley		
	35	6,861.441	03/2005	Nicholas M.Clayton et al		
	36	2002/137736	09/2002	Kenneth Mattes et al		
	39	2004/048889	03/2004	Dan Peters et al		
	46	6,878,740	04/2005	Corrina Sundermann et al		
	47	2002/040024	04/2002	Richard Apodaca et al		
	49	6,716,864	04/2004	Robert M Burk et al		
	52	6,797,712	09/2004	Corinna Maul et al		
	53	6,835,212	12/2004	Rozzell et al		
	60	2003/0195190	10/2003	Bernd Peschke et al		
	69	2004/192758	09/2004	Johann Leban et al		
	75	2005004133	01/2005	Lews R Makings et al		
	88	5,939,436	08/1999	William Robert Carling et al		
	89	5,645,566	07/1997	Rodney Brenneman et al		
	90	5,663,357	09/1997	Ming Teng et al		
_	102	2004/259880	12/2003	David J Lockhart et al	_	

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Transla Yes	ation No
3	EP1108426	06/2001	European				
10	EP661260	07/1995	European				✓
11	EP776885	06/1997	European				✓
29	WO/00/06529	02/2000	PCT				
30	WO/00/18405	04/2004	PCT				
32	WO/00/24738	05/2000	PCT				
33	WO/0040561	07/2000	PCT				
34	WO/0069987	11/2000	PCT				✓
37	WO/0157006	08/2001	PCT				
38	WO/0164676	09/2001	PCT				
40	WO/02058698	08/2002	PCT				

Examiner	Date Considered
----------	-----------------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FOREIGN PATENT DOCUMENTS

41	WO/02060898	08/2002	PCT			
42	WO/0206278	01/2002	PCT			
43	WO/02067930	09/2003	PCT			
44	WO/02067937	09/2002	PCT			
45	WO02/083624	10/2002	PCT			
48	WO02/18361	03/2002	PCT			
50	WO02/26727	04/2002	PCT			
51	WO02/40473	04/2002	PCT			
54	WO03/018585	03/2003	PCT			
55	WO0/3033503	04/2003	PCT			✓
56	WO0/3044015	05/2003	PCT			
57	WO03/053352	07/2003	PCT			
58	WO03/055479	07/2003	PCT			
59	WO03/059871	07/2003	PCT – English translation of claims only	,	/	
61	WO03/097621	11/2003	PCT			
62	WO03/097644	11/2003	PCT			
63	WO04/002948	01/2004	PCT			✓
64	WO04/011418	02/2004	PCT			
65	WO04/019932	03/2004	PCT			
66	WO04/024663	03/2004	PCT			✓
67	WO04024738	03/2004	PCT			✓
68	WO04048349	06/2004	PCT			
70	WO04069816	08/2004	PCT			
71	WO04078169	09/2004	PCT			
72	WO04089944	10/2004	PCT			
73	WO04094362	11/2004	PCT			✓
74	WO04099199	11/2004	PCT			
76	WO05079793	09/2005	PCT			
77	WO02068412	09/2002	PCT			
78	WO9601827	01/1996	PCT			
79	WO9521171	08/1995	PCT			

ı		
	Examiner	Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FOREIGN PATENT DOCUMENTS

80	WO9117163	11/1991	PCT		
81	WO9118897	12/1991	PCT		
82	WO9221644	12/1992	PCT		
83	WO9306118	04/1993	PCT		
84	WO9402460	02/1994	PCT		
85	WO9402483	02/1994	PCT		
86	WO9406796	03/1994	PCT		✓
87	WO9611911	04/1996	PCT		
91	WO9807835	02/1998	PCT		
92	WO9834909	08/1998	PCT		✓
93	WO9847894	10/1998	PCT		
94	WO9851662	11/1998	PCT		
95	WO9856783	12/1998	PCT		✓
96	WO9857925	12/1998	PCT		
97	WO9857927	12/1998	PCT		
98	WO9857928	12/1998	PCT		
99	WO9910322	03/1999	PCT		✓
100	WO9919300	04/1999	PCT		
101	WO04063194	07/2004	PCT		
103	WO9303012	02/1993	PCT		
104	WO03090869	11/2003	PCT		
105	JP10-287654	1998	Japan – English abstract only	✓	
106	JP09-311401	1997	Japan – English abstract only	✓	
107	JP11-209366	1999	Japan – English abstract only	✓	
108	JP2004-051628	2004	Japan – English abstract only	✓	
109	JP2001-139550	2001	Japan – English abstract only	✓	
110	JP07-281440	1995	Japan – English abstract only	✓	
111	JP04-253974	1992	Japan – English abstract only	✓	
112	JP03-240066	1991	Japan – English abstract only	✓	
113	JP2005-046141	2005	Japan– English abstract only	✓	
114	JP2005-41867	2005	Japan – English abstract only	✓	

Examiner	Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT ATTY. DOCKET NO. 620-288; SERIAL NO. 10/766,030; Page 5 of 5

	Richard J Davis et al. EP ₄ prostanoid receptor-mediated vasodilatation of human middle cerebral arteries. Br. J. Pharmacol. (2004) 141, 580-585

Examiner	Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.